B lymphoproliferative diseases: Effective treatment, inhibited progression, and potential cures through isoform-specific targeting of the prolactin receptor
Authors:
- 24 January 2025
- book chapter
- Published by Elsevier
- Vol. 129, 241-272
Abstract
No abstract availableKeywords
Funding Information
- Prevent Cancer Foundation
- U.S. Department of War (W81XWH-14\u20131-0425)
- National Cancer Institute
- University of California
- American Society of Hematology
- Concern Foundation
- Ono Pharmaceutical
- National Institutes of Health (R01 CA276517\u201301A1)
This publication has 164 references indexed in Scilit:
- Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta‐Analysis of the Centers for Disease Control and Prevention National Lupus RegistriesArthritis & Rheumatology, 2021
- Long term increased expression of the short form 1b prolactin receptor in PC‐3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacityThe Prostate, 2009
- Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges2009
- Prolactin in man: a tale of two promotersBioEssays, 2006
- The Risk of Lymphoma Development in Autoimmune DiseasesArchives of internal medicine (1960), 2005
- Lymphoma subtypes in patients with rheumatoid arthritis: Increased proportion of diffuse large B cell lymphomaArthritis & Rheumatism, 2003
- CD40-CD40 ligandJournal of Leukocyte Biology, 2000
- Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cellsInternational Journal of Cancer, 1999
- Prolactin receptor expression in the developing mouse embryoMolecular Reproduction and Development, 1997
- Subset-Specific Effects of Sex Hormones and Pituitary Gonadotropins on Human Lymphocyte Proliferation in VitroClinical Immunology and Immunopathology, 1993